Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srđan Verstovšek1, Ruben A. Mesa2, Jason Gotlib3, R. S. Levy4, Vikas Gupta5, John F. DiPersio6, John Catalano7, Michael W. Deininger8, Carole B. Miller9, Richard T. Silver10, Moshe Talpaz11, EF Winton12, John Collins Harvey13, Murat O. Arcasoy14, Elizabeth O. Hexner15, Roger M. Lyons16, Azra Raza17, Kris Vaddi4, William Sun4, Wei Peng4, Victor Sandor4, Hagop M. Kantarjian1
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Mayo Clinic, Scottsdale, AZ, USA
3Stanford Cancer Institute, Stanford, CA, USA
4Incyte Corporation, Wilmington, DE, USA.
5Princess Margaret Cancer Center, University of Toronto, ON, Canada
6Washington University School of Medicine. St. Louis, Mo. USA
7Frankston Hospital and Department of Clinical Haematology, Monash University, Frankston, Australia
8Oregon Health and Science University, Portland, OR, USA
9Saint Agnes Cancer Institute, Baltimore, MD, USA
10Weill Cornell Medical Center, New York, NY, USA
11University of Michigan, Ann Arbor, MI USA
12Emory University School of Medicine, Atlanta, GA, USA;
13Birmingham Hematology and Oncology, Birmingham, AL, USA
14Duke University Health System, Durham, NC, USA
15Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA.
16Cancer Care Centers of South Texas/US Oncology, San Antonio, TX, USA
17Columbia Presbyterian Medical Center, New York, NY, USA
Tóm tắt
Từ khóa
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Haematologica
Tập 100 Số 4
479-488
Thông tin tác giả